STATIN INTOLERANCE: CURRENT STATUS AND MANAGEMENT

Abstract

Statins (HMG-CoA reductase inhibitors), since their introduction in 1987 are considered the first-line pharmacotherapy for cholesterol reduction. Because of their proven therapeutic ability to prevent cardiovascular disease and to extend life, statins are among one of the most widely prescribed medications. Various randomized clinical trials have consistently shown that statins have a beneficial role in both primary and secondary prevention strategies, with a significant reduction in major vascular events, including death, myocardial infarction, stroke, and coronary revascularization[1].